- Home
- NCSM vs CUE Comparison
NCSM vs CUE Comparison
Compare NCSM & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- CUE
- Stock Information
- Founded
- NCSM 2006
- CUE 2014
- Country
- NCSM United States
- CUE United States
- Employees
- NCSM N/A
- CUE N/A
- Industry
- NCSM Oilfield Services/Equipment
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- NCSM Energy
- CUE Health Care
- Exchange
- NCSM Nasdaq
- CUE Nasdaq
- Market Cap
- NCSM 61.1M
- CUE 60.6M
- IPO Year
- NCSM 2017
- CUE 2018
- Fundamental
- Price
- NCSM $28.64
- CUE $0.76
- Analyst Decision
- NCSM
- CUE Strong Buy
- Analyst Count
- NCSM 0
- CUE 3
- Target Price
- NCSM N/A
- CUE $3.00
- AVG Volume (30 Days)
- NCSM 13.6K
- CUE 206.6K
- Earning Date
- NCSM 04-30-2025
- CUE 05-08-2025
- Dividend Yield
- NCSM N/A
- CUE N/A
- EPS Growth
- NCSM N/A
- CUE N/A
- EPS
- NCSM 2.55
- CUE N/A
- Revenue
- NCSM $162,557,000.00
- CUE $9,287,000.00
- Revenue This Year
- NCSM $7.03
- CUE N/A
- Revenue Next Year
- NCSM $5.82
- CUE $4.77
- P/E Ratio
- NCSM $11.23
- CUE N/A
- Revenue Growth
- NCSM 14.10
- CUE 69.16
- 52 Week Low
- NCSM $15.90
- CUE $0.45
- 52 Week High
- NCSM $38.95
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- NCSM 46.67
- CUE 39.49
- Support Level
- NCSM $25.09
- CUE $0.72
- Resistance Level
- NCSM $28.95
- CUE $0.89
- Average True Range (ATR)
- NCSM 2.72
- CUE 0.10
- MACD
- NCSM -0.66
- CUE 0.02
- Stochastic Oscillator
- NCSM 25.62
- CUE 48.59
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.